Krystal Biotech (KRYS) Short Interest Ratio & Short Volume $183.36 +1.67 (+0.92%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$183.32 -0.05 (-0.02%) As of 06:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Krystal Biotech Short Interest DataKrystal Biotech (KRYS) has a short interest of 3.60 million shares. This marks a 4.35% increase in short interest from the previous month. The short interest ratio (days to cover) is 10.0, indicating that it would take 10.0 days of the average trading volume of 384,057 shares to cover all short positions.Current Short Interest3,600,000 sharesPrevious Short Interest3,450,000 sharesChange Vs. Previous Month+4.35%Dollar Volume Sold Short$560.56 millionShort Interest Ratio10.0 Days to CoverLast Record DateSeptember 15, 2025Outstanding Shares28,940,000 sharesPercentage of Shares Shorted12.44%Today's Trading Volume397,457 sharesAverage Trading Volume384,057 sharesToday's Volume Vs. Average103% Short Selling Krystal Biotech? Sign up to receive the latest short interest report for Krystal Biotech and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartKRYS Short Interest Over TimeKRYS Days to Cover Over TimeKRYS Percentage of Float Shorted Over Time Krystal Biotech Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 9/15/20253,600,000 shares $560.56 million +4.4%N/A10 $155.71 8/31/20253,450,000 shares $509.57 million -0.9%13.8%9.7 $147.70 8/15/20253,480,000 shares $522.94 million +2.4%N/A9.7 $150.27 7/31/20253,400,000 shares $523.16 million +8.3%13.6%8.8 $153.87 7/15/20253,140,000 shares $463.87 million -1.3%N/A8.9 $147.73 6/30/20253,180,000 shares $437.12 million +5.0%12.8%8.6 $137.46 6/15/20253,030,000 shares $415.32 million +3.8%12.1%8.2 $137.07 5/31/20252,920,000 shares $371.02 million +12.3%11.8%8.6 $127.06 5/15/20252,600,000 shares $338.86 million +9.7%10.5%7.7 $130.33 4/30/20252,370,000 shares $402.62 million -2.1%N/A7.4 $169.88 Get the Latest News and Ratings for KRYS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. 4/15/20252,420,000 shares $409.29 million -10.7%9.8%8.5 $169.13 3/31/20252,710,000 shares $488.61 million +0.4%11.0%9.5 $180.30 3/15/20252,700,000 shares $484.33 million -2.2%10.9%9.9 $179.38 2/28/20252,760,000 shares $494.73 million -13.5%11.2%9.9 $179.25 2/15/20253,190,000 shares $488.84 million +6.0%12.9%11.9 $153.24 1/31/20253,010,000 shares $480.82 million -7.4%N/A11.5 $159.74 1/15/20253,250,000 shares $475.93 million -3.6%N/A12.2 $146.44 12/31/20243,370,000 shares $527.94 million -8.9%N/A13.6 $156.66 12/15/20243,700,000 shares $605.47 million +1.4%N/A15.4 $163.64 11/30/20243,650,000 shares $720.58 million +1.4%N/A15.5 $197.42 11/15/20243,600,000 shares $614.66 million +4.4%N/A15.7 $170.74 10/31/20243,450,000 shares $595.23 million -2.5%N/A16.1 $172.53 10/15/20243,540,000 shares $631.75 million +0.6%N/A15.6 $178.46 9/30/20243,520,000 shares $640.75 million -4.1%N/A13.9 $182.03 9/15/20243,670,000 shares $739.80 million -0.5%N/A12.9 $201.58 8/31/20243,690,000 shares $719.99 million +4.2%N/A9.5 $195.12 8/15/20243,540,000 shares $686.69 million +1.1%N/A9.1 $193.98 7/31/20243,500,000 shares $729.61 million -4.6%N/A8.8 $208.46 7/15/20243,670,000 shares $762.92 million +4.6%N/A9.4 $207.88 6/30/20243,510,000 shares $644.58 million +21.0%N/A9.1 $183.64 6/15/20242,900,000 shares $515.56 million +7.8%N/A7.7 $177.78 5/31/20242,690,000 shares $430.53 million -4.3%N/A8.6 $160.05 5/15/20242,810,000 shares $458.56 million +8.5%N/A7.5 $163.19 4/30/20242,590,000 shares $396.58 million +5.7%N/A6.6 $153.12 4/15/20242,450,000 shares $415.89 million +12.9%N/A6.2 $169.75 3/31/20242,170,000 shares $386.11 million -3.1%N/A5.5 $177.93 3/15/20242,240,000 shares $387.48 million -10.8%N/A5.8 $172.98 2/29/20242,510,000 shares $400.27 million +1.6%N/A6.5 $159.47 2/15/20242,470,000 shares $280.05 million +21.7%N/A7.3 $113.38 1/31/20242,030,000 shares $225.84 million +3.1%N/A6.6 $111.25 1/15/20241,970,000 shares $252.87 million -9.2%N/A6.3 $128.36 12/31/20232,170,000 shares $269.21 million +11.3%N/A7.1 $124.06 12/15/20231,950,000 shares $225.73 million -8.0%N/A6.4 $115.76 11/30/20232,120,000 shares $220.97 million +2.4%N/A6.8 $104.23 11/15/20232,070,000 shares $206.09 million -1.4%N/A6.8 $99.56 10/31/20232,100,000 shares $245.43 million +7.1%N/A7.1 $116.87 10/15/20231,960,000 shares $223.01 million -0.5%N/A7.4 $113.78 9/30/20231,970,000 shares $228.52 million +23.9%N/A7.4 $116.00 9/15/20231,590,000 shares $191.07 million +6.0%N/A5.9 $120.17 8/31/20231,500,000 shares $186.72 million -2.6%N/A5.7 $124.48 8/15/20231,540,000 shares $187.82 million +15.8%N/A5.3 $121.96 7/31/20231,330,000 shares $171.70 million -7.6%N/A4.1 $129.10 7/15/20231,440,000 shares $181.83 million +6.7%6.8%4.7 $126.27 6/30/20231,350,000 shares $158.49 million +3.1%6.4%4.5 $117.40 6/15/20231,310,000 shares $163.37 million +10.1%6.2%4.3 $124.71 5/31/20231,190,000 shares $140.24 million +3.5%5.6%4.3 $117.85 5/15/20231,150,000 shares $103.56 million -0.9%5.5%4.4 $90.05 4/30/20231,160,000 shares $97.44 million -7.2%5.5%5.7 $84.00 4/15/20231,250,000 shares $107.98 million +4.2%6.0%6.4 $86.38 3/31/20231,200,000 shares $96.07 million +5.3%5.8%5.9 $80.06 3/15/20231,140,000 shares $83.80 million -4.2%5.5%5.9 $73.51 2/28/20231,190,000 shares $97.47 million +6.3%5.7%6.3 $81.91 2/15/20231,120,000 shares $82.33 million +6.7%5.4%6.5 $73.51 1/31/20231,050,000 shares $87.28 million -7.1%5.1%6.1 $83.12 1/15/20231,130,000 shares $93.73 million +14.4%5.4%6.5 $82.95 12/30/2022988,100 shares $78.28 million -10.2%4.8%5.9 $79.22 12/15/20221,100,000 shares $86.24 million -9.1%5.3%6.9 $78.40 11/30/20221,210,000 shares $94.07 million -3.2%5.9%7.8 $77.74 11/15/20221,250,000 shares $96.51 million -4.6%6.1%7.7 $77.21 10/31/20221,310,000 shares $100.22 million +3.2%6.4%7.9 $76.50 10/15/20221,270,000 shares $83.83 million -3.1%6.2%7.6 $66.01 9/30/20221,310,000 shares $91.31 million +7.4%6.4%7.9 $69.70 9/15/20221,220,000 shares $86.97 million -4.7%6.3%7.3 $71.29 8/31/20221,280,000 shares $89.74 million -5.9%6.6%7.2 $70.11 8/15/20221,360,000 shares $105.48 million -0.7%7.0%7.9 $77.56 7/31/20221,370,000 shares $99.43 million -1.4%7.0%7.5 $72.58 7/15/20221,390,000 shares $100.66 million -10.9%7.1%7.7 $72.42 6/30/20221,560,000 shares $102.43 million -2.5%7.9%8.6 $65.66 6/15/20221,600,000 shares $85.34 million +0.6%8.1%8.4 $53.34 5/31/20221,590,000 shares $93.62 million -1.2%8.1%7.8 $58.88 5/15/20221,610,000 shares $90.77 million +2.6%8.2%7.6 $56.38 4/30/20221,570,000 shares $95.16 million -7.1%8.1%7.4 $60.61 4/15/20221,690,000 shares $122.51 million +5.0%8.7%8 $72.49 3/31/20221,610,000 shares $107.13 million +17.5%8.4%7.2 $66.54 3/15/20221,370,000 shares $84.98 million +13.2%7.1%6.3 $62.03 2/28/20221,210,000 shares $76.90 million +4.3%6.4%5.2 $63.55 2/15/20221,160,000 shares $78.11 million +9.4%N/A2.6 $67.34 1/31/20221,060,000 shares $62.54 million -1.9%5.6%2.4 $59.00 1/15/20221,080,000 shares $67.26 million +4.9%5.7%2.4 $62.28 12/31/20211,030,000 shares $72.05 million -25.4%5.4%2.4 $69.95 12/15/20211,380,000 shares $99.98 million -37.6%7.3%3.3 $72.45 11/30/20212,210,000 shares $178.02 million +6.8%12.3%5.7 $80.55 11/15/20212,070,000 shares $98.22 million +12.5%12.9%13.6 $47.45 10/29/20211,840,000 shares $92.17 million +5.8%11.5%14.2 $50.09 10/15/20211,740,000 shares $84.77 million +13.0%10.8%15 $48.72 9/30/20211,540,000 shares $80.40 million -0.7%9.6%13.6 $52.21 9/15/20211,550,000 shares $86.89 million -4.3%9.7%12.5 $56.06 8/31/20211,620,000 shares $93.86 million +12.5%10.1%12.6 $57.94 8/13/20211,440,000 shares $80.90 million +7.5%9.0%11.6 $56.18 7/30/20211,340,000 shares $78.31 million +24.1%8.4%10.9 $58.44 7/15/20211,080,000 shares $67.46 million -1.8%6.8%9.3 $62.46 6/30/20211,100,000 shares $74.80 million -4.4%6.9%10.1 $68.00 6/15/20211,150,000 shares $72.91 million -0.9%7.2%11.8 $63.40 5/28/20211,160,000 shares $75.68 million -4.1%7.3%11.5 $65.24 5/14/20211,210,000 shares $75.67 million -2.4%7.6%10.7 $62.54 4/30/20211,240,000 shares $99.35 million +3.3%7.8%9.2 $80.12 4/15/20211,200,000 shares $89.72 million -3.2%7.5%8 $74.77 3/31/20211,240,000 shares $90.43 million +6.9%7.9%8 $72.93 3/15/20211,160,000 shares $96.06 million -2.5%7.4%7.1 $82.81 2/26/20211,190,000 shares $93.87 million +10.2%7.9%7.3 $78.88 2/12/20211,080,000 shares $74.19 million -10.7%7.2%6.5 $68.69 1/29/20211,210,000 shares $85.51 million -6.2%8.1%7.3 $70.67 1/15/20211,290,000 shares $85.58 million -5.8%9.6%8.6 $66.34 12/31/20201,370,000 shares $82.76 million +2.2%10.2%9.3 $60.41 12/15/20201,340,000 shares $78.26 million -2.2%10.0%9 $58.40 11/30/20201,370,000 shares $66.94 million -4.2%10.2%9.8 $48.86 11/15/20201,430,000 shares $59.89 million -7.1%10.7%10.6 $41.88 10/30/20201,540,000 shares $69.79 million -11.0%11.5%12.1 $45.32 10/15/20201,730,000 shares $86.60 million -3.9%13.0%13.6 $50.06 KRYS Short Interest - Frequently Asked Questions What is Krystal Biotech's current short interest? Short interest is the volume of Krystal Biotech shares that have been sold short but have not yet been closed out or covered. As of September 15th, investors have sold 3,600,000 shares of KRYS short. Learn More on Krystal Biotech's current short interest. What is a good short interest ratio for Krystal Biotech? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. KRYS shares currently have a short interest ratio of 10.0. Learn More on Krystal Biotech's short interest ratio. Which institutional investors are shorting Krystal Biotech? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Krystal Biotech: Nomura Holdings Inc., LMR Partners LLP, Group One Trading LLC, Nantahala Capital Management LLC, Jane Street Group LLC, and Caption Management LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Krystal Biotech's short interest increasing or decreasing? Krystal Biotech saw a increase in short interest in September. As of September 15th, there was short interest totaling 3,600,000 shares, an increase of 4.3% from the previous total of 3,450,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Krystal Biotech's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Krystal Biotech: Genmab A/S Sponsored ADR (0.57%), Summit Therapeutics PLC (4.34%), Dr. Reddy's Laboratories Ltd (1.19%), Ascendis Pharma A/S (3.71%), Viatris Inc. (3.67%), Roivant Sciences Ltd. (8.72%), QIAGEN N.V. (3.10%), Elanco Animal Health Incorporated (5.51%), BridgeBio Pharma, Inc. (10.17%), Moderna, Inc. (18.43%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Corporation ($8.81 billion), Canadian Natural Resources Limited ($5.82 billion), Reddit Inc. ($5.19 billion), Coinbase Global, Inc. ($4.52 billion), Robinhood Markets, Inc. ($4.30 billion), Charter Communications, Inc. ($3.75 billion), CoreWeave Inc. ($3.66 billion), Seagate Technology Holdings PLC ($3.57 billion), Live Nation Entertainment, Inc. ($3.33 billion), and Rocket Lab Corporation ($3.26 billion). View all of the most shorted stocks. What does it mean to sell short Krystal Biotech stock? Short selling KRYS is an investing strategy that aims to generate trading profit from Krystal Biotech as its price is falling. KRYS shares are trading up $1.67 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Krystal Biotech? A short squeeze for Krystal Biotech occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of KRYS, which in turn drives the price of the stock up even further. How often is Krystal Biotech's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KRYS, twice per month. The most recent reporting period available is September, 15 2025. More Short Interest Resources from MarketBeat Related Companies GMAB Short Interest Data SMMT Short Interest Data RDY Short Interest Data ASND Short Interest Data VTRS Short Interest Data ROIV Short Interest Data QGEN Short Interest Data ELAN Short Interest Data BBIO Short Interest Data MRNA Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:KRYS) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Krystal Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
